Cubist's 2Q revenue jumps 30% on mainstay 'building blocks'
This article was originally published in Scrip
Cubist Pharmaceuticals reported a second consecutive quarter of 30% revenue growth and a 19% boost in sales for Cubicin (daptomycin), its antibiotic to treat serious infections in hospital settings, marking a strong start to its five-year "Building Blocks of Growth" plan.
You may also be interested in...
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.
Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.